FilingReader Intelligence
Junshi Biosciences' toripalimab approved for advanced HCC treatment
March 27, 2025 at 10:04 PM UTC•By FilingReader AI
Shanghai Junshi Biosciences (HKEX: 1877) announced that it has received approval from China's National Medical Products Administration for its supplemental new drug application for toripalimab (TUOYI®) in combination with bevacizumab. This approval designates the combination therapy as a first-line treatment for patients with unresectable or metastatic HCC.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1877•Hong Kong Exchange
News Alerts
Get instant email alerts when Junshi BIO publishes news
Free account required • Unsubscribe anytime